{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"limitationsAndCaveats":{"description":"Study stopped after the first stage due to lack of patients meeting the defined primary objective (50% decline in M-protein). The study did not continue to the second stage of enrollment due to lack of efficacy as defined by our criteria."},"pointOfContact":{"email":"kazandjiandg@mail.nih.gov","organization":"National Cancer Institute","phone":"301-480-0532","title":"Dr. Dickran Kazandijian"}}